{"title": "Nanocarriersysteme als neues Therapiekonzept bei entz\u00fcndlichen Mundschleimhaut- und Parodontalerkrankungen", "author": "Jager; Juliane", "url": null, "hostname": null, "description": "The special characteristics of the oral cavity challenge the pharmaceutical treatment of inflammatory diseases of the oral mucosa. Constant salivation and mechanical load of the mucosa sites limit the substantivity and efficacy of conventional, locally applied drugs. The particularly high prevalence of oral mucosal diseases therefore requires novel therapeutical approaches. Recently developed nanoparticles can be used for drug transport and delivery. They are considered as a promising new therapeutical option to overcome the epithelial barrier. In recent years, many of them have been successfully tested on human skin. Although skin and gingiva show various structural similarities a careful evaluation of the safety and efficacy of those systems on oral mucosa is mandatory. Core-multishell (CMS) nanocarriers and thermosensitive N-isopropylmethacrylamide (NIPMAM) nanogels are two different examples of nanosized carriersystems which differ in architecture. In the present study the CMS nanocarriers 10-A-18-350 and 10-E-15-350 as well as a PNIPMAM-(S-S)-dPG nanogel have been characterized. For this purpose, in vitro toxicity and proliferation assays have been performed using immortalized gingival keratinocytes. None of the carrier systems tested showed cytotoxic effects. However, the application of CMS nanocarrier 10-E-15-350 on monolayer cultures showed a slight increase of cell metabolism, whereas the used PNIPMAM-(S-S)-dPG nanogel slightly decreased the metabolic activity of gingival keratinocytes. Cell count, however, stayed unaltered. To investigate the penetration efficacy of the nanocarrier systems into oral mucosa, Franz cell penetration studies have been performed and analyzed via confocal microscopy. As those experiments require a relatively large size of tissue samples, porcine mucosa was used. Keratinized and non-keratinized mucosa tissues have been examined. Both CMS nanocarrier types and the PNIPMAM-(S-S)-dPG nanogel were capable of penetrating each type of mucosal tissue. The penetration was limited to the upper cell layers and did not exceed Stratum corneum. Franz cell experiments and subsequent electron paramagnetic resonance spectroscopy (EPR) analysis were performed to examine the release of a model drug loaded to the CMS 10-E-15-350 nanocarrier. Here, the glucocorticoid dexamethasone was used. The results show the ability of CMS 10-E-15-350 to deliver dexamethasone into mucosal tissues of keratinized and non-keratinized type. The CMS-nanocarrier showed a considerably improved dexamethasone release compared to a conventional cream formulation. Taken together, nanosized carrier systems could provide a novel approach for the delivery of compounds to diseased areas of the oral mucosa. Further investigation should be conducted particularly with regard to the CMS nanocarrier 10-A-18-350 and 10-E-15-350.", "sitename": null, "date": "2021-12-03", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "The special characteristics of the oral cavity challenge the pharmaceutical treatment of inflammatory diseases of the oral mucosa. Constant salivation and mechanical load of the mucosa sites limit the substantivity and efficacy of conventional, locally applied drugs. The particularly high prevalence of oral mucosal diseases therefore requires novel therapeutical approaches. Recently developed nanoparticles can be used for drug transport and delivery. They are considered as a promising new therapeutical option to overcome the epithelial barrier. In recent years, many of them have been successfully tested on human skin. Although skin and gingiva show various structural similarities a careful evaluation of the safety and efficacy of those systems on oral mucosa is mandatory. Core-multishell (CMS) nanocarriers and thermosensitive N-isopropylmethacrylamide (NIPMAM) nanogels are two different examples of nanosized carriersystems which differ in architecture. In the present study the CMS nanocarriers 10-A-18-350 and 10-E-15-350 as well as a PNIPMAM-(S-S)-dPG nanogel have been characterized. For this purpose, in vitro toxicity and proliferation assays have been performed using immortalized gingival keratinocytes. None of the carrier systems tested showed cytotoxic effects. However, the application of CMS nanocarrier 10-E-15-350 on monolayer cultures showed a slight increase of cell metabolism, whereas the used PNIPMAM-(S-S)-dPG nanogel slightly decreased the metabolic activity of gingival keratinocytes. Cell count, however, stayed unaltered. To investigate the penetration efficacy of the nanocarrier systems into oral mucosa, Franz cell penetration studies have been performed and analyzed via confocal microscopy. As those experiments require a relatively large size of tissue samples, porcine mucosa was used. Keratinized and non-keratinized mucosa tissues have been examined. Both CMS nanocarrier types and the PNIPMAM-(S-S)-dPG nanogel were capable of penetrating each type of mucosal tissue. The penetration was limited to the upper cell layers and did not exceed Stratum corneum. Franz cell experiments and subsequent electron paramagnetic resonance spectroscopy (EPR) analysis were performed to examine the release of a model drug loaded to the CMS 10-E-15-350 nanocarrier. Here, the glucocorticoid dexamethasone was used. The results show the ability of CMS 10-E-15-350 to deliver dexamethasone into mucosal tissues of keratinized and non-keratinized type. The CMS-nanocarrier showed a considerably improved dexamethasone release compared to a conventional cream formulation. Taken together, nanosized carrier systems could provide a novel approach for the delivery of compounds to diseased areas of the oral mucosa. Further investigation should be conducted particularly with regard to the CMS nanocarrier 10-A-18-350 and 10-E-15-350.\nDie Mundh\u00f6hle stellt mit ihren Eigenschaften besondere Anforderungen an die Therapie von Mundschleimhauterkrankungen. Die topische Anwendung von konventionellen Therapeutika ist aufgrund der st\u00e4ndigen Umsp\u00fclung mit Speichel und der mechanischen Beanspruchung der Schleimhautoberfl\u00e4che wenig effizient. Die im Kontrast dazu stehende, hohe Pr\u00e4valenz von Erkrankungen der Mundschleimhaut erfordert deshalb eine Weiterentwicklung der Therapieans\u00e4tze. Neu entwickelte Nanocarriersysteme dienen dem Transport und der Freisetzung von Wirkstoffen. Sie stellen eine vielversprechende Therapieoption dar, um die Barriere des Epithels zu \u00fcberwinden. Viele dieser Systeme wurden in den vergangenen Jahren f\u00fcr ihren Einsatz an \u00e4u\u00dferer Haut getestet. Durch ihren strukturell \u00e4hnlichen Aufbau kommt auch die Mundschleimhaut als Zielgewebe solcher neuer Therapiestrategien in Frage. Ultrastrukturelle Unterschiede fordern jedoch eine sorgf\u00e4ltige \u00dcberpr\u00fcfung der Effektivit\u00e4t und Sicherheit solcher Systeme beim Einsatz an oraler Schleimhaut. Zwei unterschiedlich aufgebaute Nanocarriersysteme sind Core-multishell-(CMS)-Nanocarrier und thermosensitive dPG-Nanogele. Die CMS-Nanocarrier 10-A-18-350 und 10-E-15-350 sowie ein thermoresponsives PNIPMAM-(S-S)-dPG-Nanogel wurden im Rahmen dieser Arbeit mittels in vitro Zytotoxizit\u00e4ts- und Proliferationsassays auf ihre Wirkung auf immortalisierte gingivale Keratinozyten \u00fcberpr\u00fcft. Es ergaben sich keine zelltoxischen Effekte f\u00fcr die CMS Nanocarrier oder das PNIPMAM-(S-S)-dPG-Nanogel. Letzteres zeigte jedoch eine geringf\u00fcgige, vor\u00fcbergehende Abschw\u00e4chung des Zellmetabolismus. Die Zellzahl blieb unbeeinflusst. Der CMS-Nanocarrier 10-E-15-350 erh\u00f6hte die metabolische Aktivit\u00e4t geringf\u00fcgig. Um die F\u00e4higkeit der genannten Systeme zur Penetration von Schleimhaut zu untersuchen, wurden Penetrationsstudien in Franz-Zellen mit fluoreszenzmarkierten Nanocarriern und -gelen durchgef\u00fchrt und mittels Laserkonfokalmikroskopie analysiert. Hierbei wurden unverhornte und verhornte Schleimhautproben vom Schwein als Referenzmodell herangezogen. Alle getesteten Systeme waren in der Lage in die Schleimhaut einzudringen. Die Penetration war auf die obersten Zellschichten begrenzt und \u00fcberschritt nicht das Stratum corneum. Mittels Elektronenspinresonanz wurde ebenfalls im Franz-Zell-Experiment die F\u00e4higkeit des CMS 10-E-15-350-Nanocarriers zur Abgabe eines Modellwirkstoffes in die Schleimhaut untersucht. Als Wirkstoff wurde das Glukokortikoid Dexamethason gew\u00e4hlt. In beiden Schleimhauttypen konnte eine Freisetzung in der Epidermis nachgewiesen werden. Besonders bei verhornter Schleimhaut war eine st\u00e4rkere Anreicherung des Wirkstoffs nach Applikation des Nanocarriers im Vergleich zu einer konventionellen Darreichungsform nachweisbar. Die Untersuchungen belegen, dass vor allem die eingesetzten CMS-Nanocarrier m\u00f6gliche Transportvehikel f\u00fcr Wirkstoffe zur Therapie von Mundschleimhauterkrankungen darstellen k\u00f6nnten und zu diesem Zweck weiter untersucht werden sollten.", "language": null, "image": null, "pagetype": null, "links": ["https://www.fu-berlin.de/", "https://www.fu-berlin.de/", "/login", "https://www.fu-berlin.de/sites/refubium", "/contact", "https://www.fu-berlin.de/sites/refubium/ueber-uns/impressum", "https://www.fu-berlin.de/sites/refubium/ueber-uns/datenschutz/", "https://refubium.fu-berlin.de:443/handle/fub188/31681?locale-attribute=en", "#", "/login", "/", "/discover", "#", "#", "/community-list", "/browse?type=author", "/browse?type=subjectDDC", "/browse?type=affiliation", "/browse?type=doctype", "/browse?type=subject", "/browse?type=title", "#", "/handle/fub188/13/browse?type=author", "/handle/fub188/13/browse?type=subjectDDC", "/handle/fub188/13/browse?type=affiliation", "/handle/fub188/13/browse?type=doctype", "/handle/fub188/13/browse?type=subject", "/handle/fub188/13/browse?type=title", "#", "/login", "/register", "/handle/fub188/31681/statistics", "/", "/handle/fub188/1", "/handle/fub188/13", "https://refubium.fu-berlin.de/handle/fub188/31681", "http://dx.doi.org/10.17169/refubium-31412", "http://nbn-resolving.de/urn:nbn:de:kobv:188-refubium-31681-6", "https://doi.org/10.1111/jre.12487", "/handle/fub188/31681?show=full", "/handle/fub188/13", "/bitstream/handle/fub188/31681/diss_j.jager.pdf?sequence=1&isAllowed=y", "/bitstream/handle/fub188/31681/diss_j.jager.pdf?sequence=1&isAllowed=y", "/bitstream/handle/fub188/31681/diss_j.jager.pdf?sequence=1&isAllowed=y&save=y", "http://www.fu-berlin.de/sites/refubium/rechtliches/Nutzungsbedingungen", "/export/handle/fub188/31681/excel", "/export/handle/fub188/31681/csv", "/export/handle/fub188/31681/bibtex", "/contact", "https://www.fu-berlin.de/sites/refubium/ueber-uns/impressum", "https://www.fu-berlin.de/sites/refubium/ueber-uns/datenschutz/", "javascript:window.print()", "/feedback", "https://www.fu-berlin.de/sites/refubium", "http://www.dini.de/dini-zertifikat/", "#"]}